Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.43 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.43 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.43 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 7/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31658013 | 1.00 | TLR9 (0.43) | TLR9TLR7CXCR2KRASEGFR | |
| SCHEMBL18128368 | 0.94 | TLR9 (0.45) | TLR9TLR7CXCR2KRASEGFR | |
| SCHEMBL31658008 | 0.94 | TLR9 (0.45) | TLR9TLR7CXCR2KRASEGFR | |
| SCHEMBL18128573 | 0.91 | TLR9 (0.41) | TLR9TLR7CXCR2KRASEGFR | |
| SCHEMBL18128388 | 0.91 | KRAS (0.45) | TLR9TLR7CXCR2KRASEGFR | |
| SCHEMBL31657979 | 0.91 | KRAS (0.45) | TLR9TLR7CXCR2KRASEGFR | |
| SCHEMBL18128527 | 0.91 | KRAS (0.45) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL20970429 | 0.90 | TLR9 (0.48) | TLR9TLR7CXCR2KRASEGFR | |
| SCHEMBL18128438 | 0.89 | KRAS (0.45) | TLR9TLR7CXCR2KRASEGFR | |
| SCHEMBL19412038 | 0.89 | TLR9 (0.43) | TLR9TLR7CXCR2KRASEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50490-E1 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190284144-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2019-09-19 | — | — | US | disclosed |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3280708-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284144-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | TLR9 4089/4885TLR7 2362/4885CXCR2 212/4885 |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | TLR9 4089/4885TLR7 2362/4885CXCR2 212/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | TLR9 4089/4885TLR7 2362/4885CXCR2 212/4885 |
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | TLR9 4089/4885TLR7 2362/4885CXCR2 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.